Cargando…
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently limited. Materials and methods: This was a dual-cen...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234690/ https://www.ncbi.nlm.nih.gov/pubmed/35770100 http://dx.doi.org/10.3389/fphar.2022.919652 |
_version_ | 1784736137677373440 |
---|---|
author | Li, Hong-Shuai Yang, Guang-Jian Cai, Yi Li, Jun-Ling Xu, Hai-Yan Zhang, Tao Zhou, Li-Qiang Wang, Yu-Ying Wang, Jin-Liang Hu, Xing-Sheng Yan, Xiang Wang, Yan |
author_facet | Li, Hong-Shuai Yang, Guang-Jian Cai, Yi Li, Jun-Ling Xu, Hai-Yan Zhang, Tao Zhou, Li-Qiang Wang, Yu-Ying Wang, Jin-Liang Hu, Xing-Sheng Yan, Xiang Wang, Yan |
author_sort | Li, Hong-Shuai |
collection | PubMed |
description | Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently limited. Materials and methods: This was a dual-center, single-arm, ambispective cohort study in China. Patients with histologically confirmed metastatic or recurrent NSCLC harboring major uncommon EGFR mutations were eligible for the study. The objective response rate and disease control rate were determined by RECIST 1.1 every 1–2 months. Adverse events were assessed by CTCAE 5.0. Results: In total, 32 NSCLC patients were enrolled between July 2020 and January 2022, and 18 (56.3%) patients received dacomitinib as first-line therapy. Median age was 64 years, and 20 (62.5%) were female. The mutations identified were G719X (n = 24; 75%), followed by L861X (n = 10; 31.3%), and S768I (n = 8; 25%). In the first-line setting, 72.2% of patients (13/18) had a confirmed partial response and 100% (18/18) had disease control, and the median progression-free survival (PFS) and overall survival (OS) were unreached. In the whole cohort, 56.3% of patients (18/32) had a confirmed partial response and 90.6% (29/32) had disease control, and the median PFS was 10.3 months (95% confidence interval, 6.1–14.5) and the median OS was 36.5 months. Except for one case not available for brain re-evaluation, control of the intracranial metastases was observed in 13 patients (13/14, 92.9%). No grade 4–5 adverse events (AEs) occurred, but all patients had grade 1–2 AEs, and 12.5% (4/32) patients required a dosage reduction due to intolerable AEs. Conclusions: Dacomitinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring major uncommon EGFR mutations. |
format | Online Article Text |
id | pubmed-9234690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92346902022-06-28 Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China Li, Hong-Shuai Yang, Guang-Jian Cai, Yi Li, Jun-Ling Xu, Hai-Yan Zhang, Tao Zhou, Li-Qiang Wang, Yu-Ying Wang, Jin-Liang Hu, Xing-Sheng Yan, Xiang Wang, Yan Front Pharmacol Pharmacology Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently limited. Materials and methods: This was a dual-center, single-arm, ambispective cohort study in China. Patients with histologically confirmed metastatic or recurrent NSCLC harboring major uncommon EGFR mutations were eligible for the study. The objective response rate and disease control rate were determined by RECIST 1.1 every 1–2 months. Adverse events were assessed by CTCAE 5.0. Results: In total, 32 NSCLC patients were enrolled between July 2020 and January 2022, and 18 (56.3%) patients received dacomitinib as first-line therapy. Median age was 64 years, and 20 (62.5%) were female. The mutations identified were G719X (n = 24; 75%), followed by L861X (n = 10; 31.3%), and S768I (n = 8; 25%). In the first-line setting, 72.2% of patients (13/18) had a confirmed partial response and 100% (18/18) had disease control, and the median progression-free survival (PFS) and overall survival (OS) were unreached. In the whole cohort, 56.3% of patients (18/32) had a confirmed partial response and 90.6% (29/32) had disease control, and the median PFS was 10.3 months (95% confidence interval, 6.1–14.5) and the median OS was 36.5 months. Except for one case not available for brain re-evaluation, control of the intracranial metastases was observed in 13 patients (13/14, 92.9%). No grade 4–5 adverse events (AEs) occurred, but all patients had grade 1–2 AEs, and 12.5% (4/32) patients required a dosage reduction due to intolerable AEs. Conclusions: Dacomitinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring major uncommon EGFR mutations. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9234690/ /pubmed/35770100 http://dx.doi.org/10.3389/fphar.2022.919652 Text en Copyright © 2022 Li, Yang, Cai, Li, Xu, Zhang, Zhou, Wang, Wang, Hu, Yan and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Hong-Shuai Yang, Guang-Jian Cai, Yi Li, Jun-Ling Xu, Hai-Yan Zhang, Tao Zhou, Li-Qiang Wang, Yu-Ying Wang, Jin-Liang Hu, Xing-Sheng Yan, Xiang Wang, Yan Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China |
title | Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China |
title_full | Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China |
title_fullStr | Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China |
title_full_unstemmed | Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China |
title_short | Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China |
title_sort | dacomitinib for advanced non-small cell lung cancer patients harboring major uncommon egfr alterations: a dual-center, single-arm, ambispective cohort study in china |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234690/ https://www.ncbi.nlm.nih.gov/pubmed/35770100 http://dx.doi.org/10.3389/fphar.2022.919652 |
work_keys_str_mv | AT lihongshuai dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT yangguangjian dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT caiyi dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT lijunling dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT xuhaiyan dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT zhangtao dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT zhouliqiang dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT wangyuying dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT wangjinliang dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT huxingsheng dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT yanxiang dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina AT wangyan dacomitinibforadvancednonsmallcelllungcancerpatientsharboringmajoruncommonegfralterationsadualcentersinglearmambispectivecohortstudyinchina |